- Home
- SRPT vs NBIX Comparison
SRPT vs NBIX Comparison
Compare SRPT & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRPT
- NBIX
- Stock Information
- Founded
- SRPT 1980
- NBIX 1992
- Country
- SRPT United States
- NBIX United States
- Employees
- SRPT N/A
- NBIX N/A
- Industry
- SRPT Biotechnology: Pharmaceutical Preparations
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SRPT Health Care
- NBIX Health Care
- Exchange
- SRPT Nasdaq
- NBIX Nasdaq
- Market Cap
- SRPT N/A
- NBIX 12.2B
- IPO Year
- SRPT 1997
- NBIX 1996
- Fundamental
- Price
- SRPT $18.20
- NBIX $129.40
- Analyst Decision
- SRPT Buy
- NBIX Strong Buy
- Analyst Count
- SRPT 25
- NBIX 20
- Target Price
- SRPT $64.00
- NBIX $163.20
- AVG Volume (30 Days)
- SRPT 7.8M
- NBIX 809.5K
- Earning Date
- SRPT 08-06-2025
- NBIX 07-31-2025
- Dividend Yield
- SRPT N/A
- NBIX N/A
- EPS Growth
- SRPT N/A
- NBIX N/A
- EPS
- SRPT N/A
- NBIX 2.96
- Revenue
- SRPT $2,233,371,000.00
- NBIX $2,412,600,000.00
- Revenue This Year
- SRPT $26.87
- NBIX $16.29
- Revenue Next Year
- SRPT $3.15
- NBIX $15.08
- P/E Ratio
- SRPT N/A
- NBIX $43.74
- Revenue Growth
- SRPT 59.15
- NBIX 21.73
- 52 Week Low
- SRPT $16.88
- NBIX $84.23
- 52 Week High
- SRPT $156.70
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- SRPT 22.90
- NBIX 65.65
- Support Level
- SRPT $16.88
- NBIX $125.02
- Resistance Level
- SRPT $18.62
- NBIX $128.66
- Average True Range (ATR)
- SRPT 1.43
- NBIX 2.78
- MACD
- SRPT -0.16
- NBIX -0.19
- Stochastic Oscillator
- SRPT 6.20
- NBIX 86.97
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.